Clinical trials · Texas
Leukemia clinical trials in Texas
We’re tracking 218 recruiting leukemia studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT07033598RecruitingPhase 2
Pacritinib or hydroxyurea for advanced CMML
This trial tests whether pacritinib works better than hydroxyurea for people with advanced proliferative chronic myelomonocytic leukemia (CMML). It may help if your white blood cell count is high and you have an enlarged spleen, severe symptoms, or low platelets.
Houston, TexasAges 18 years+ - NCT06973187RecruitingPhase 3
Comparing two drugs for CLL or SLL after prior treatment
This trial tests a new drug (BGB-16673) against another drug (pirtobrutinib) for people with CLL or SLL that hasn't responded to or has come back after a prior BTK inhibitor treatment. The goal is to see which drug is more effective and safe.
Houston, TexasAges 18 years+ - NCT06969430RecruitingPhase 1/Phase 2
Debio 1562M for relapsed or refractory AML
This trial tests a new drug called Debio 1562M for people with AML that has not responded to treatment or has come back. It aims to see if the drug is safe and can help fight the leukemia.
Houston, TexasAges 18 years+ - NCT06967610RecruitingPhase 2
Pirtobrutinib, venetoclax, and obinutuzumab for recurrent CLL/SLL
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
Houston, TexasAges 18 years+ - NCT06846671RecruitingPhase 3
Study of a new drug for CLL or SLL
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Temple, TexasAges 18 years+ - NCT06852222RecruitingPhase 3
Study of bleximenib, venetoclax, and azacitidine for newly diagnosed AML
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Houston, TexasAges 18 years+ - NCT06817720RecruitingPhase 2
Olverembatinib for newly diagnosed chronic phase CML
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
Houston, TexasAges 18 years+ - NCT06811233RecruitingPhase 2
Metal detox during AML treatment
This trial tests whether monitoring and rebalancing metals in the body can help improve treatment for adults with acute myeloid leukemia (AML) or related conditions. It's for patients who are getting their first or second round of therapy and aren't yet in remission.
Houston, TexasAges 18 years+ - NCT06769490RecruitingPhase 1
Ziftomenib and Quizartinib combination for AML
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
Houston, TexasAges 18 years+ - NCT06680752RecruitingPhase 1/Phase 2
A car-t cell therapy trial for AML or MDS
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
Houston, TexasAges 18 years+ - NCT06616636RecruitingPhase 1
Rezatapopt and azacitidine for AML or MDS with a specific TP53 mutation
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
Houston, TexasAges 18 years+ - NCT06549790RecruitingPhase 1
Study of NMS-03597812 for relapsed or refractory AML
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
Houston, TexasAges 18 years+ - NCT06561074RecruitingPhase 2
Study of calaspargase, decitabine, and venetoclax for young T-cell cancer
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
Houston, TexasAges 1 month–21 years - NCT06566742RecruitingPhase 2
Olutasidenib for IDH1-mutated blood disorders
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
Houston, TexasAges 18 years+ - NCT06548230RecruitingPhase 1/Phase 2
Nadunolimab plus azacitidine for MDS and AML
This trial tests a new combination of drugs (nadunolimab plus azacitidine, sometimes with venetoclax) for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has not been treated much or has come back. The goal is to see if this combination can control the disease better.
Houston, TexasAges 18 years+ - NCT06514794RecruitingPhase 2
A study of a new cell therapy for T-cell acute lymphoblastic leukemia and lymphoma
This trial tests an investigational cell therapy that uses donated immune cells to find and destroy cancer cells in patients with T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or not responded to treatment. The goal is to see if this therapy can help achieve remission for these patients.
San Antonio, TexasAges 6 months+ - NCT04150497RecruitingPhase 1/Phase 2
Testing a new cell therapy for CD22-positive leukemia
This trial tests UCART22, a new cell-based treatment, for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) that has the CD22 marker. It may help by attacking leukemia cells that carry CD22.
Austin, TexasAges 15–50 - NCT06448013RecruitingPhase 1
Ziftomenib with chemo for pediatric AML
This trial tests a new drug, ziftomenib, combined with two standard chemotherapies (venetoclax and gemtuzumab) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells.
Houston, TexasAges 3–21 - NCT06428019RecruitingPhase 3
Comparing drug combinations for untreated CLL or SLL
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Austin, TexasAges 18 years+ - NCT06397027RecruitingPhase 1
Ziftomenib, venetoclax, and azacitidine for pediatric leukemia
This trial tests a new drug combination (ziftomenib, venetoclax, and azacitidine) in children and young adults with acute leukemia that has come back or not responded to treatment. It may help if your child's leukemia has certain genetic changes (like KMT2A, NPM1, or NUP98).
Houston, TexasAges 2–21 - NCT06317649RecruitingPhase 2
Venetoclax with hypomethylating agents for older or unfit adults with FLT3-mutated AML
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
Houston, TexasAges 18 years+ - NCT06308588RecruitingPhase 1/Phase 2
Blinatumomab and asciminib for Ph+ ALL
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
Houston, TexasAges 18 years+ - NCT06285890RecruitingPhase 1
HC-7366 study for relapsed or refractory AML
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
Houston, TexasAges 18 years+ - NCT06287229RecruitingPhase 1/Phase 2
CAR T therapy for B-cell ALL after initial treatment
This trial tests whether a special immune cell therapy (brexucabtagene autoleucel, or CAR T therapy) can help people with B-cell acute lymphocytic leukemia (ALL) after reducing the number of leukemia cells with a chemo-immunotherapy combination. It is for patients whose cancer has returned or is hard to treat, or for those newly diagnosed with a high-risk form of ALL.
Houston, TexasAges 18 years+
Leukemia trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting leukemia studies listed above.
- The University of Texas MD Anderson Cancer Center · 21 studies
- Baylor College of Medicine
- Baylor Scott and White Health
- Baylor University Medical Center
- Ben Taub General Hospital
- Houston Methodist Hospital
- Sarah Cannon - St. David's South Austin Medical Center
- Sarah Cannon - Texas Transplant Institute at Methodist Hospital
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Leukemia trials in other states
Common questions
- Are there leukemia clinical trials in Texas?
- Yes. We're currently tracking 218 recruiting leukemia studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.